Reagents for Lipid Nanoparticles

Description

JenKem Technology provides large scale GMP manufacture of high purity lipids and PEG-lipids for Lipid Nanoparticles (LNPs) for commercial pharmaceutical applications and clinical trials. Please contact us for a quotation.

• Large scale GMP manufacture of conventional lipid products (cationic lipids, ionizable lipids, PEG lipids, phospholipids, helper lipids, SORT lipids, and others made-to-order)
• Innovative lipid products (i.e., JK-0315, JK-102, JK-0039) and LNP formulation development, such as Innovative 3-component LNPs and 5-component LNPs for selective organ targeting
• CDMO services for Lipid products (lipid process development, quality research, CDE/DMF application)
• LNP encapsulation services
• Analytical testing services (for LNP, RNA, LNP-RNA)

Cationic Lipids for LNPs Offered by JenKem Technology:

DOTAP (1,2-dioleoyl-3-trimethylammonium propane, chloride salt)

Phospholipids (Helper Lipids) for LNPs Offered by JenKem Technology:

DSPC ((R)-2,3bis(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate)

PEG Lipids for LNPs Offered by JenKem Technology:

and many other PEG lipid derivatives and intermediates.
*Products marked with * may require a license or authorization in certain jurisdictions. Please contact us for details.

Ionizable Lipids for LNPs Offered by JenKem Technology:

and many other lipids.
*Products marked with * may require a license or authorization in certain jurisdictions. Please contact us for details.

 

LNPs drug delivery systems are commonly employed for nucleic acid drugs. LNPs are generally believed to
combine with the cell membrane through noncovalent affinity and absorbed by endocytosis. After being absorbed by the cell, the mRNA delivered by LNPs are released to the cytoplasm and express the target protein, escaping from the endocytosis. This technology has been adopted by pharmaceutical companies in the recent years for COVID-19 vaccine manufacture.

References:

1. Wu, W., et al., Preclinical efficacy of engineered CircRNA-GDF15@LNP for sustained weight loss and metabolic regulation in diet-induced obese mice, Journal of Controlled Release, 397, 2026.
2. Liu, S., et al, Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma, Molecular Therapy Nucleic Acids, 37(1), 2026.
3. Wang, Z., et al., Ionizable Sterol Lipid-Based Three-Component Lipid Nanoparticles for Localized Delivery of mRNA Vaccine with Stronger Cellular Immune Responses, ACS Applied Materials & Interfaces, 2025. DOI: 10.1021/acsami.5c04597
4. Ma, Y., et al.,  Hepatocyte-targeted lipid nanoparticle for full-length ATP7B mRNA delivery in Wilson disease, Journal of Controlled Release, 388 (1), 2025
5. Guo, Z., et al., Vascular endothelial cell-targeted mRNA delivery via synthetic lipid nanoparticles for venous thrombosis prevention, Journal of Controlled Release, 388 (2), 2025
6. Liu, M., et al., Branched ligand-functionalized immuno-evasive PEGylation (BLIP) platform: Breaking through accelerated blood clearance and chemoresistance barriers with dual-targeting RNAi-chemotherapy synergy, Chemical Engineering Journal, 522, 2025
7. Liang, Z., et al., Galactose receptor-mediated hepatic targeting system: engineering of quinary cationic liposomes for resveratrol delivery against hepatic steatosis, RSC Advances, 15 (25), 2025
8. Jiang, F., et al., LNP-miR-155 cy5 Inhibitor Regulates the Copper Transporter via the β-Catenin/TCF4/SLC31A1 Signal for Colorectal Cancer Therapy, Molecular Pharmaceutics 2023 20 (8), 4138-4152
9. Schoenmaker, Linde, et al., mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability, International Journal of Pharmaceutics 2021, 601
10. Gu, T., et al., Intratumoural delivery of TRAIL mRNA induces colon cancer cell apoptosis, Biomedicine & Pharmacotherapy, 2024, V. 174. Keywords: mRNA; Lipid nanoparticles; apoptosis; death receptors; TRAIL; SM-102; DMG-PEG2000
11. Wang, Q., et al., A pro-metastatic tRNA fragment drives aldolase A oligomerization to enhance aerobic glycolysis in lung adenocarcinoma, Cell Reports, 2024, V. 43, 8. Keywords: Methoxypoly (ethylene glycol)-ditetradecylacetamide (ALC-0159)

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, co-polymers, lipids, fatty acid side chains, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7 guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.